ANTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. AN2 Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0. AN2 Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-25), AN2 Therapeutics's share price is $2.40. AN2 Therapeutics's Median PS Value is $0.00. Therefore, AN2 Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for AN2 Therapeutics's Median PS Value or its related term are showing as below:
The historical data trend for AN2 Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Median PS Value | - | - | - | - |
AN2 Therapeutics Quarterly Data | |||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, AN2 Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's Price-to-Median-PS-Value falls into.
AN2 Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
AN2 Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (NAS:ANTX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
AN2 Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 2.40 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of AN2 Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
Kabeer Aziz | director | 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211 |
Adjuvant Global Health Technology Fund De, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Robin Shane Readnour | director | 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215 |
Kevin Michael Krause | officer: Chief Strategy Officer | 369 27TH STREET, SAN FRANCISCO CA 94131 |
Eric Easom | director, officer: Chief Executive Officer | 171 FOREST LN., MENLO PARK CA 94025 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Joshua M Eizen | officer: See Remarks | 3023 MONTBRETIA WAY, SAN RAMON CA 94582 |
Margaret M Fitzpatrick | director | C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080 |
Ra Capital Nexus Fund Ii, L.p. | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Melvin K Spigelman | director | THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Sanjay Chanda | officer: Chief Development Officer | C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Adjuvant Global Health Technology Fund, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Michael Adrian Nazak | officer: Chief Accounting Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Lucy Day | officer: Chief Financial Officer | 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
From GuruFocus
By PurpleRose PurpleRose • 08-11-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By Business Wire Business Wire • 03-29-2023
By GuruFocus Research GuruFocus Editor • 05-16-2023
By Business Wire Business Wire • 05-01-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By Business Wire • 08-16-2023
By Business Wire • 10-18-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.